Hazel dormice: Rare rodents reintroduced in Leicestershire to boost numbers
Conservationists have released more than twenty rare hazel dormice into a secret woodland location in Leicestershire.The project is part of national efforts to help the tiny endangered species return from the brink of extinction.It follows a similar successful reintroduction of the mammals to the National Forest, in neighbouring Derbyshire.The hope is that these two groups of dormice will one day form part of a wider population spanning the whole area.
What have wildlife experts done with the dormice?
Experts say that numbers of hazel dormice have fallen by around 70% nationally in the past twenty five years.Despite once being common across Britain, they have experienced a big drop in numbers for many reasons but particularly because of loss of habitat - places to live such as woods and hedgerows. The way woods and hedgerows are maintained has also impacted their survival as the tiny mice need dense, varied woodlands to hide and survive.According to a recent report, the species is thought to now be extinct in 20 English counties.The dormice were reintroduced this week to a secret location within the Bradgate Park Trust estate in Leicestershire by a team of experts, including wildlife charity People's Trust for Endangered Species (PTES).To help them adapt to their new environment, the animals will be first housed in open enclosures for more than a week, before being fully released into the wild.
Ian White from PTES said that the reintroduction could be an important step in starting a new population of dormice.He explained: "It's a big day for the county, as dormice haven't been seen here for a very long time."We're hopeful that by autumn, the dormice will have settled into the woodland. If we start to see litters later this year, it will mark the beginning of their return," Mr White added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
2 hours ago
- Telegraph
Planking is a miracle exercise – here's how to get it right
A good few hours and too many G&Ts after watching the World Cup Final in 2018, I found myself nose down in a forearm plank, on the floor of a friend's sitting room. Next to me was a similarly braced male acquaintance, whose challenge I had accepted. Minutes passed before we both started to show signs of strain. Five minutes in, my core was still intact, but my knuckles were whitening. As we passed the 10-minute mark, everyone else, luckily, had grown bored of our bravado and we were able to settle on an amicable draw; egos intact. The plank, an isometric core-strength exercise that involves maintaining a position similar to a push-up for the maximum possible time, is both feared and prized in fitness circles. The benefits of planking There are many benefits of planking, including: Strengthen core muscles Lower blood pressure Low impact Helps reduce risk of injury Plank is an isometric exercise, meaning it creates tension in the muscle to help build strength without any movement. One 2022 study found that the plank and other isometric exercises such as wall sits and leg extensions are better at preventing high blood pressure than going for a run, walk or a bike ride. Scientists at Canterbury Christ Church University, in Kent, reviewed more than 200 trials which looked at a range of exercises and how they impacted blood pressure.
The Guardian
5 hours ago
- The Guardian
‘Transformative': the UK lab working on a way to halt genetic type of dementia
Behind the gleaming glass facade of an office block in east London's docklands, Dr Martina Esposito Soccoio is pipetting ribonucleic acid into test tubes. Here, not far from Canary Wharf's multinational banks, a British university spinout is working on a breakthrough treatment for a form of dementia suffered by millions of people worldwide. There is no cure for dementia at present, but scientists at AviadoBio hope their clinical studies can stop the progression of a particular genetic type of frontotemporal dementia (FTD). 'It may be one of the first dementias to have a definitive treatment, a cure if you like, a really transformative treatment that allows people to live much longer and much more normal lives,' says Prof James Rowe, consultant neurologist at Cambridge's Addenbrooke's Hospital. FTD mainly affects the front and sides of the brain and unlike Alzheimer's disease, does not begin with memory loss, which tends to occur later. It is characterised by progressive loss of language and changes in personality and behaviour. Most cases are diagnosed in people aged 45 to 65, but it can affect people in their 20s and 30s. There are an estimated 20,000 to 40,000 people living with FTD in the UK, and between 1m and 2m in the world. Rowe says: 'It's a double-edged sword: the young onset, the high genetic burden and rapid illness are also features that perhaps make it more tractable to treat.' The Die Hard and Pulp Fiction actor Bruce Willis, who recently celebrated his 70th birthday, was diagnosed with FTD two years ago, with his family calling it a 'cruel disease'. They have not said whether he has a genetic form of FTD. The gene therapy developed by AviadoBio, which was spun out of Prof Christopher Shaw's research lab at King's College London in 2021, targets a type of FTD known as FTD-GRN. This is caused by mutations of a gene that lead to a deficiency of progranulin (GRN), a protein that is essential for maintaining healthy brain cells. AviadoBio, which employs 60 people, signed an exclusive licence agreement with the Japanese pharma firm Astellas last October to develop the therapy. It is now recruiting patients for its clinical trial in the UK, as well as the US, Poland, Spain, Sweden and the Netherlands. The first patient received the infusion in Warsaw in March 2024, out of six patients who have had the treatment so far, in Poland and the US. All patients will be followed for up to five years as part of the trial. AviadoBio expects to publish the first data next year. Three years ago, Jessica Crawford, from Beverley in Yorkshire, lost her mother to FTD, caused by mutations of another gene, C9orf72. In 2014, when her mother was 58, her behaviour changed; the family suspected depression. Previously very sociable, she stopped going out and started playing games like Candy Crush or watching TV shows 'over and over,' her daughter recounts. Her mother initially did not want to see a doctor, and was only diagnosed with FTD in February 2019. By this time she was so confused she once put raw chicken in a sandwich. 'Getting the diagnosis wasn't easy because FTD wasn't well known; my mum was aceing in the memory tests,' Crawford says. But her mother became increasingly confused and lost the ability to speak, and to communicate at all. Crawford became her full-time carer in 2020, until her mother deteriorated so much that she had to go to a care home in late 2021, and died the following year. Crawford, 33, found out that she herself carries the gene mutation, and with her husband decided to conceive through IVF with a pre-implantation genetic diagnosis. When their five embryos were screened, four had the gene mutation, and the fifth resulted in the birth of their son. The couple donated their other four embryos to science and she takes part in GENFI – a long-running UK-led global study of families with FTD across 40 sites. AviadoBio itself was born out of the research done at King's by Shaw, a neurologist who has focused on FTD and amyotrophic lateral sclerosis (ALS) for more than three decades, and Dr Youn Bok Lee and Dr Do Young Lee from the UK Dementia Research Institute's centre based at King's. ALS, the most common form of motor neurone disease, has also been linked to mutations of the GRN gene and leads to muscle weakness, paralysis and eventually death. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion Shaw acts as the company's chief scientific and clinical adviser, and while the Lees are no longer involved in the firm's research, all three remain shareholders. David Cooper, AviadoBio's chief medical officer, says: 'It was something that hit me when I first joined the company, you look at the MRI scans of patients with a GRN mutation, the frontal and temporal parts of their brain are just melting away … So we really need earlier treatment, an, earlier diagnosis and a more organised healthcare approach to deal with it.' AviadoBio's lead product, known as AVB-101, is infused directly into the brain by a neurosurgeon using a cannula as thin as a strand of angel hair pasta, during a 90-minute procedure guided by MRI. It delivers a functional copy of the progranulin gene to restore appropriate levels of the protein to affected areas of the brain. It is a once-only treatment, and no immunosuppressant drugs are needed subsequently. 'The patients who have FTD are born with almost half of the progranulin levels that you and I might have,' says chief executive Lisa Deschamps. 'Our goal in the study is to supplement the GRN gene and restore as much progranulin in these individuals as possible to normal levels to reduce the neurodegeneration effect. Other medications in development at AviadoBio include two gene therapies, from Philadelphia-based Passage Bio and Eli Lilly-owned Prevail Therapeutics, but they do not target the thalamus, the 'relay station' in the brain. Passage Bio's therapies are delivered directly to the cerebrospinal fluid in a single treatment. Denmark's Vesper Bio has developed an oral capsule, designed to act on the GRN gene, that is being trialled at University College London Hospital. AviadoBio, whose investors include Johnson & Johnson's innovation arm and the UK not-for-profit LifeArc Ventures, is part of a growing life science cluster in Canary Wharf. At its labs, scientists – assisted by robotics – research how to target a particular gene. 'The UK has real strengths in this area,' says Rowe, pointing to the international GENFI study, run since 2011 by Prof Jonathan Rohrer, a neurologist from UCL Queen Square Institute of Neurology who also sits on AviadoBio's scientific advisory board. 'It's a real win for the UK.'
BBC News
6 hours ago
- BBC News
Livingstone's fruit bat pups born at Jersey Zoo
Twelve pups of an endangered species of bat have been born at Jersey Livingstone's fruit bat pups were born a couple of weeks after 10 adult bats died from an the diagnosis of Pasteurellosis, a bacterial infection, the 80-strong colony was removed from the public viewing area, split into four groups and the bats were given intensive treatment.A spokesperson for the zoo said there had been no further deaths and the bat pups and their mothers were "doing well". The spokesperson said work to develop a vaccine to prevent another outbreak was underway and it would be the first for bats for this type of bacteria. They said: "As with any new process, it involves working through things systematically and thoroughly."The team is now considering options for returning the bats to public Durrell Wildlife Conservation Trust which owns the zoo said its population makes up 75% of the global captive population of Livingstone's fruit trust said there are about 1,000 of the species living in the wild, on the Anjouan and Mohéli islands of the Comoros in the Indian Ocean.
